Werewolf Therapeutics Inc... (HOWL)
Werewolf Therapeutics Statistics
Share Statistics
Werewolf Therapeutics has 44.83M shares outstanding. The number of shares has increased by 3.16% in one year.
Shares Outstanding | 44.83M |
Shares Change (YoY) | 3.16% |
Shares Change (QoQ) | 0.59% |
Owned by Institutions (%) | 64.45% |
Shares Floating | 33.13M |
Failed to Deliver (FTD) Shares | 45 |
FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 1.86M, so 4.17% of the outstanding shares have been sold short.
Short Interest | 1.86M |
Short % of Shares Out | 4.17% |
Short % of Float | 5.64% |
Short Ratio (days to cover) | 5.42 |
Valuation Ratios
The PE ratio is -0.91 and the forward PE ratio is -1.01. Werewolf Therapeutics's PEG ratio is -0.02.
PE Ratio | -0.91 |
Forward PE | -1.01 |
PS Ratio | 34.02 |
Forward PS | 0.2 |
PB Ratio | 0.87 |
P/FCF Ratio | -1.14 |
PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Werewolf Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.15.
Current Ratio | 7.45 |
Quick Ratio | 7.45 |
Debt / Equity | 0.15 |
Debt / EBITDA | -0.17 |
Debt / FCF | -0.19 |
Interest Coverage | -15.81 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $40.98K |
Profits Per Employee | $-1.53M |
Employee Count | 46 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -86.83% in the last 52 weeks. The beta is 0.48, so Werewolf Therapeutics's price volatility has been higher than the market average.
Beta | 0.48 |
52-Week Price Change | -86.83% |
50-Day Moving Average | 1.25 |
200-Day Moving Average | 1.91 |
Relative Strength Index (RSI) | 23.75 |
Average Volume (20 Days) | 267.49K |
Income Statement
In the last 12 months, Werewolf Therapeutics had revenue of 1.89M and earned -70.52M in profits. Earnings per share was -1.63.
Revenue | 1.89M |
Gross Profit | 1.89M |
Operating Income | -73.59M |
Net Income | -70.52M |
EBITDA | -64.05M |
EBIT | -65.86M |
Earnings Per Share (EPS) | -1.63 |
Balance Sheet
The company has 112.22M in cash and 10.99M in debt, giving a net cash position of 101.22M.
Cash & Cash Equivalents | 112.22M |
Total Debt | 10.99M |
Net Cash | 101.22M |
Retained Earnings | -414.59M |
Total Assets | 126.93M |
Working Capital | 97.89M |
Cash Flow
In the last 12 months, operating cash flow was -56.19M and capital expenditures -254K, giving a free cash flow of -56.44M.
Operating Cash Flow | -56.19M |
Capital Expenditures | -254K |
Free Cash Flow | -56.44M |
FCF Per Share | -1.3 |
Margins
Gross margin is 100%, with operating and profit margins of -3904.19% and -3740.85%.
Gross Margin | 100% |
Operating Margin | -3904.19% |
Pretax Margin | -3740.85% |
Profit Margin | -3740.85% |
EBITDA Margin | -3397.61% |
EBIT Margin | -3904.19% |
FCF Margin | -2994.27% |
Dividends & Yields
HOWL does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for HOWL is $8, which is 912.7% higher than the current price. The consensus rating is "Buy".
Price Target | $8 |
Price Target Difference | 912.7% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | -4.95 |
Piotroski F-Score | 3 |